YaoGeJu

Company directoryChina company filings

Chongqing Rui En Pharmaceuticals Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference acf005746e

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

17 acceptance records as first applicant, grouped into 10 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Orlistat Capsules 1 records · Latest accepted 2026/08/13

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601547Supplement2026/08/13Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Chongqing Hua Sen Pharmaceutical Co., Ltd. romanizedCDE ↗
Ziprasidone Hydrochloride Capsules 2 records · Latest accepted 2026/01/23

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600263Generic2026/01/23Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
CYHS2600262Generic2026/01/23Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Trazodone Hydrochloride Sustained-release Tablets 2 records · Latest accepted 2025/08/27

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503145Generic2025/08/27Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
CYHS2503144Generic2025/08/27Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Levodopa and Benserazide Hydrochloride Tablets 1 records · Latest accepted 2025/02/18

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500784Generic2025/02/18Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Tandospirone Citrate Tablets 1 records · Latest accepted 2023/09/05

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301983Supplement2023/09/05Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
Memantine Hydrochloride Tablets 2 records · Latest accepted 2023/07/12

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301559Supplement2023/07/12Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHB2301082Supplement2023/05/18Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
Trimetazidine Dihydrochloride Tablets 3 records · Latest accepted 2023/03/30

Supplement · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300644Supplement2023/03/30Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
CYHB2300643Supplement2023/03/30Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
CYHB2340008Supplement2023/02/09Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Ropinirole Hydrochloride Tablets 2 records · Latest accepted 2023/03/30

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2300646Supplement2023/03/30Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
CYHB2300645Supplement2023/03/30Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Metformin Hydrochloride Extended-release Tablets 1 records · Latest accepted 2022/01/17

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2200154Supplement2022/01/17Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanizedCDE ↗
Quetiapine Fumarate Extended-release Tablets 2 records · Latest accepted 2022/01/05

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2200002Supplement2022/01/05Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanizedCDE ↗
CYHB2200001Supplement2022/01/05Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Ziprasidone Hydrochloride Capsules CYHS2600263Generic2026/01/23Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Ziprasidone Hydrochloride Capsules CYHS2600262Generic2026/01/23Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Trazodone Hydrochloride Sustained-release Tablets CYHS2503145Generic2025/08/27Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗
Trazodone Hydrochloride Sustained-release Tablets CYHS2503144Generic2025/08/27Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanizedCDE ↗

Catalogue holder records

2 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Tandospirone Citrate TabletsChongqing Rui En Pharmaceuticals Co., Ltd. romanizedHuayi Pharmaceuticals (Anhui) Co., Ltd.国药准字H202437952024/05/21Generic approved under the new chemical-drug registration classificationCDE ↗
Trimetazidine Dihydrochloride TabletsChongqing Rui En Pharmaceuticals Co., Ltd. romanizedZhi En Bio Technology Co., Ltd. romanized国药准字H202040342024/03/22Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.